Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,822.67 | 0.67 | 0.01% |
| DAX 40 | 24,289.51 | 81.42 | -0.33% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,992.12 | 19.48 | 0.22% |
| HKSE | 24,825.66 | 326.71 | 1.33% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |